Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS.
Giovanni NoviFederico IvaldiElvira SbragiaMalgorzata MikulskaGiampaola PesceMatilde IngleseNicole Kerlero de RosboAntonio UccelliPublished in: Neurology(R) neuroimmunology & neuroinflammation (2020)